ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC.
about
The basal transcription machinery as a target for cancer therapyNew potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer.Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.Perspective: Opportunities in recalcitrant, rare and neglected tumors.Oxyphenisatin acetate (NSC 59687) triggers a cell starvation response leading to autophagy, mitochondrial dysfunction, and autocrine TNFα-mediated apoptosis.Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.Nucleoside analog ARC targets Mcl-1 to induce apoptosis in leukemia cells.Synthesis of purine and 7-deazapurine nucleoside analogues of 6-N-(4-Nitrobenzyl)adenosine; inhibition of nucleoside transport and proliferation of cancer cells.Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response.Development of high-content imaging assays for lethal viral pathogens.First total synthesis of a naturally occurring iodinated 5'-deoxyxylofuranosyl marine nucleoside.Protein kinase C: an attractive target for cancer therapy.The expression of miRNAs is associated with tumour genome instability and predicts the outcome of ovarian cancer patients treated with platinum agents.Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides.Therapy-induced stress response is associated with downregulation of pre-mRNA splicing in cancer cells.
P2860
Q21246017-4D30950E-0CDD-4A02-B0EC-99E517DA836BQ33920494-A46673E9-AF25-43B0-9E94-A6956409261BQ33925043-3A78463C-CF30-447A-BE10-3FE5E4F8D300Q37197528-B0DF41C8-ADD9-4EAA-8E5B-C4E441563A52Q37482581-637FBBD5-7BD4-454D-86A0-0D8DB0853043Q38008733-65CD353A-F675-459A-BEBC-3F19FFF2424CQ38828546-20F295E8-177A-4EB5-973A-BFDB61CE3D2FQ38999625-C7753A50-8F87-4BDC-8961-37D5C53EF6E4Q39281937-F89793E9-1571-4355-BE2D-3F0ABFE6D2CAQ39360397-5C1A2C5E-EE9A-4EF0-98D8-E46AF962B4B0Q40353545-ADE79B73-2B37-4C93-9069-FC434E8592C5Q41878901-AFB074BC-D2C3-4688-9A2E-CC61B402EA7FQ41971372-4B5885E8-E2DA-43D4-901A-DD3FD16FE679Q44959100-B107BDC7-AA85-4C47-856C-717DD1F9988EQ47095447-CDBDB1A7-D900-4157-9DD4-565C6533719BQ55449946-D0672DC4-1CC9-40E8-AB1D-7FEE65F8F2AC
P2860
ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
ARC (NSC 188491) has identical ...... bition of both P-TEFb and PKC.
@ast
ARC (NSC 188491) has identical ...... bition of both P-TEFb and PKC.
@en
type
label
ARC (NSC 188491) has identical ...... bition of both P-TEFb and PKC.
@ast
ARC (NSC 188491) has identical ...... bition of both P-TEFb and PKC.
@en
prefLabel
ARC (NSC 188491) has identical ...... bition of both P-TEFb and PKC.
@ast
ARC (NSC 188491) has identical ...... bition of both P-TEFb and PKC.
@en
P2093
P2860
P356
P1433
P1476
ARC (NSC 188491) has identical ...... bition of both P-TEFb and PKC.
@en
P2093
Dianne L Newton
Howard Stotler
Luke H Stockwin
Melinda G Hollingshead
Sherry X Yu
P2860
P2888
P356
10.1186/1471-2407-9-63
P407
P577
2009-02-20T00:00:00Z
P5875
P6179
1025712195